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Abstract
Background: Bone necrosis of the jaw is a serious condition with a broad differential diagnosis of pathologies such
as cutaneous histiocytosis, bone metastases or malignant tumours. In addition to the most common cause,
medication related osteonecrosis of the jaw (MRONJ), one must consider a number of other causes, such as
histiocytosis.
Langerhans cell histiocytosis (LCH) is a histiocytic disorder with a large spectrum of clinical manifestations and with
possible involvement of a variety of organs. This case shows the importance of an early detection of this rare
disease in order to prevent further spreading. Even if an initial diagnosis in the oral cavity is rare, dentists should be
aware of this disease.
Case presentation: The presented case describes a patient who was referred for evaluation and treatment due to
exposed bone and extensive osteolysis in the region of the upper and lower jaw. After biopsy and diagnosis of LCH,
the patient was treated with systemic therapy, achieved remission and is disease free after a 2 year of follow up.
Conclusions: This case report illustrates that when dealing with unclear osteolytic changes of the jawbone,
Langerhans cell histiocytosis must be taken into consideration in the differential diagnosis and biopsy must be
performed in case of suspicion.
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Background
Langerhans cell histiocytosis (LCH), formerly known
under a variety of different names such as histiocytosis
X, eosinophilic granuloma, Hand-Schüller-Christian dis-
ease or Letterer-Siwe disease, is a rare disease of the
family of histiocytosis characterized by the accumulation
of histiocytic cells in various tissues. The discovery of
Birbeck granules in the histiocytes of this disease and
the expression of similar antigens has led to the name
Langerhans cell histiocytosis. However newer findings
show that LCH origins from dendritic myeloid progeni-
tor cells rather than Langerhans cells of the skin [1].
LCH has a relatively higher incidence in children under
the age of 15 years (5:1′000’000) but can also occur
more rarely in adults (around 1:1′000’000). The etiology
of the disease is still unknown, and there has been con-
siderable debate whether LCH represents an inflammatory
or a neoplastic disease. The discovery of recurrent muta-
tions in the mitogen activated protein kinase (MAPK)
pathway (i.e. BRAF and MAP2K1 mutations) indicates
that it is a neoplastic disease [2, 3]. Recently the Histiocyte
Society has published a revised classification of histiocy-
toses in which LCH is sub classified according to site of
manifestation and organ involvement: single system LCH,
lung LCH and multi system LCH with or without risk
organ involvement (risk organs: liver, spleen, bone mar-
row) [4]. Single system LCH affecting the skin or bone are
the most frequent clinical manifestations, other less fre-
quent sites of involvement include: pituitary gland, liver,
spleen, bone marrow, lungs, lymph nodes and the central
nervous system, although every organ can be affected.
Lung LCH is considered separately in the classification, as
it is very frequently associated with cigarette smoking,
occurs predominantly in adults and is considered a form
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of interstitial lung disease [5]. A small, but not neglectable
number of patients with multisystem, cranial or facial
bone osteolytic lesions may develop diabetes insipi-
dus, caused by lesions of the neurohypophysis or the
supraoptic and paraventricular nuclei, sometimes
representing the initial manifestation of the disease
[6]. The clinical symptoms of LCH are usually seen
as a secondary consequence of organ dysfunction.
Skin lesions may present as papules or eczematous le-
sions, isolated or generealised [5]. Patients with bone
LCH most often present localized pain and swelling
of the affected area, sometimes with concurrent fever
and the most commonly affected bones are the skull
and the jawbone. In the oral region reported symp-
toms are gingivitis, periodontitis, tooth rotation or
loss and malocclusion [7].
Possible differential diagnoses of LCH are other cuta-
neous histiocytoses such as xanthogranulomas, normoli-
pemic granulomas, histiocytomas or haemophagocytic
lymphohistiocytosis and should be considered [8]. In the
present case the clinical presentation is difficult to be
distinguished from medication related osteonecrosis of
the jaw (MRONJ) or possible neoplastic lesions. Definite
diagnosis will be achieved by the histopathological
examination [9].
This case report informs the readership on methods of
clinical and radiographic examination as well as treat-
ment of this rare disease on the basis of this case. The
importance of a thorough dental examination has also
been underlined in a case of oral Multisystem LCH [10].
Although LCH is rare, it should be considered as a po-
tential diagnosis.
Case presentation
A 46-year-old male patient was examined in May 2015
due to tympanic effusion and right-sided hearing loss.
The patient had a history of diabetes insipidus centralis
of unknown aetiology, diagnosed in 2008. A 18F-fluor-
o-D-deoxyglucose (FDG) positron emission tomography
/computed tomography (PET/CT) showed multiple
FDG-avid lesions in the skull base, the temporal bone,
the mandible and maxilla, but no lesions outside the
head and neck area. Magnetic resonance imaging (MRI)
Fig. 1 Clinical presentation of dehiscent gingiva in the mandible (a) and maxilla (b)
Fig. 2 Baseline FDG-PET/CT scan shows lytic lesions in the right
mandible (a, arrow) and left maxilla (b, arrow) with intense
radiotracer uptake
Fig. 3 Coronal PET image in maximum intensity projection shows
the FDG-avid lysis in the mandible on the right side and in the
maxilla on the left side, as well as other FDG-avid lytic lesions in the
right-sided mastoid process as well as in the right-sided skull base
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of the same region showed a mass in the right-sided
infratemporal fossa, erosions of the skull base and the
alveolar ridge.
Due to the osteolysis of both the upper and lower jaw,
the patient was transferred to our clinic. Here we con-
ducted a cone beam computed tomography (CBCT) to
determine the extent of the osteolysis. Clinically, an ex-
posed alveolar ridge and ulcerative granulation tissue
was present in region 45–47 and in the left upper jaw
(Fig. 1a, b). Past medical history revealed that multiple
teeth had been extracted by different dentists, and that
the extraction sites showed prolonged or incomplete
healing.
Findings on magnetic resonance imaging (MRI)
Initially, the MRI showed an infiltrating mass in the cen-
tral part of the right medial infratemporal fossa. There
were osseous defects in other areas of the skull base and
in the lower right alveolar ridge.
Findings on positron emission tomography/computed
tomography (PET/CT)
The PET/CT of the skull, showed complete obliteration
of the right middle ear and the mastoid cells as well as a
soft tissue swelling in the external auditory canal of the
right temporal bone. Further, a soft tissue lesion was
seen in the right-sided skull base involving the temporal
bone. FDG-PET/CT confirmed increased metabolic
activity of the lesions in the right infratemporal fossa,
in the tip of the mastoid and in the right horizontal
mandibular ramus Fig. 2a, b). The localization of the
other lesions is shown in Fig. 3. The biggest and most
important lesion was situated in the right skull base
with lysis of the petrous apex, the otic capsule, clivus,
carotid canal, hypoglossal canal, jugular foramen and
expansion in the retrostyloid space. No other clinical
factors were present and there was no evidence of
metabolically active local lymph nodes.
Findings on cone beam computed tomography (CBCT)
As the low-dose CT scan from PET/CT did not allow
sufficient assessment of the mandibular bone structures,
a CBCT was performed at our clinic (Accuitomo 170,
Morita, Japan). The CBCT showed significant bone loss
in the right mandible up to the level of the inferior al-
veolar nerve. In the left upper jaw, a complete resorption
of the alveolar ridge was seen (Fig. 4a, b).
Histopathological findings
As the MRI showed a necrotic tumour in the region of
the petrous apex, this area was selected for biopsy. Due
to the delicate location of the bone lesion between the
temporal bone and the middle ear, a preliminary com-
puter assisted transnasal biopsy was carried out by the
ENT department. The biopsy was taken from the
pharyngeal recess in the right nasopharynx next to the
Fig. 4 The baseline CBCT shows bone resorption in the right mandible and the left maxilla in a reconstructed panoramic view (a) and bone
resorption in the right mandible in a 3D-reconstruction (b)
Fig. 5 Photomicrographs show histiocytic infiltrates (a) with marked eosinophilia (b) (Hematoxylin and Eosin stain)
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petrous apex. Biopsy samples showed respiratory mucosa
fragments with chronic and partially purulent inflamma-
tion with focal eosinophilia. No evidence of malignancy
was seen, ancillary histochemical stainings showed no
evidence of fungal infection. A second, more extensive
excisional biopsy showed soft tissue with chronic inflam-
mation and marked eosinophilia (Fig. 5). At high power
magnification mononuclear histiocytic cells with irregu-
lar nuclei admixed with small lymphocytes and eosino-
philic granulocytes were observed, raising suspicion for a
histiocytic disorder. Immunohistochemical stains
highlighted expression of CD1a, Langerin (CD207) and
S-100 (Fig. 6a, b, c), consistent with the diagnosis of
Langerhans cell histiocytosis. Molecular studies showed
absence of mutations in Exon 15 of the BRAF gene (i.e.
no BRAF V600E mutation), instead a 6 base pair dele-
tion in exon 3 of the MAP2K1 gene (p.E102_I103del)
was found. A bone marrow biopsy ruled out infiltration
by LCH. Lumbal puncture revealed no evidence of ma-
lignant cells.
Therapy and surgical intervention
Diabetes insipidus centralis, which was persisting since
eight years, was defined as having been caused by the
LCH. The interdisciplinary tumour board, based on the
extension of the disease with affection of the skull base,
decided to treat the patient with chemotherapy
(Cytarabine). As this disease is rare in adults, there is
currently no randomized clinical trial in adults and no
therapeutic standard is defined. Retrospective data indi-
cates that Cytarabine is more effectively compatible in
adults with LCH with predominant involvement of the
bone and the central nervous system compared to the
pediatric standard of Vinblastin/Prednison [11]. Prior to
this treatment, tooth 48 was extracted due to extensive
perifocal bone resorption. The chemotherapy was con-
ducted with Cytarabin (150 mg/m2 day 1−5 intravenous
during one hour, repetition day 29). Further a PET/CT
was taken two and six months after the start of the
chemotherapy. After that, PET/CT’s were taken every
6 months. After six cycles of chemotherapy, the patient
clinically showed complete soft tissue healing (Fig. 7a, b)
and stable bone lesions in the CBCT (Fig. 8a, b).
FDG-PET/CT showed a significant metabolic response
of lesions (Fig. 9a, b). Overall, the patient primarily re-
ceived 12 cycles of chemotherapy, and due to residual
activity, another six cycles of chemotherapy. Two years
after diagnosis the patient is in good general condition
with no signs of recurrent disease.
Discussion and conclusions
LCH is a rare disease and by virtue of this, at great risk
of being under- or misdiagnosed. It is therefore of ut-
most importance that LCH is kept in mind when dealing
Fig. 7 Clinical presentation of right crestal mandibular (a) and left crestal maxillary (b) gingiva at follow-up after eight months of chemotherapy
Fig. 6 Immunohistochemistry shows the typical LCH phenotype CD1a (a), Langerin (b) and S-100 (c)
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with unclear osteolytic bone lesions, especially in the ab-
sence of exposure to drugs associated with osteonecrosis
(e.g. bisphosphonates). In our case report two biopsies
were necessary to diagnose the patient’s condition,
highlighting the challenge of sampling error. Bone scan
may be falsely negative in osseous LCH. FDG-PET/CT
was shown to be a reliable tool in the assessment of pa-
tients with various histiocytic diseases, including LCH.
FDG-PET/CT can identify active lesions, guide biopsy,
and assess the response to treatment [12, 13]. Literature
on manifestations in the oral region is limited and
mostly consists of case reports or retrospective series
[14–16]. Surgical treatment has been shown to be very
effective in the treatment of localised oral manifestations
of LCH and is usually regarded as being sufficient as a
sole treatment, sometimes combined with steroid injec-
tions [16, 17]. If surgical removal of the affected area is
not possible or if LCH reoccurs in the same location, ra-
diation therapy may serve as an alternative or second
line treatment [18]. In severe cases with organ dysfunc-
tion or systemic LCH manifestations, chemotherapy sig-
nificantly improves the outcome, however due to the
rareness of the disease, it is still unclear which regimens
are best suited for different clinical situations [11]. With
the recent discovery of the molecular pathology of the
disease, targeted therapy might represent a future treat-
ment option [19]. As other rare diseases, international
collaborations are needed to conduct clinical trials,
The Histiocyte Society (Histiocyte Society Home.
Available at: http://www.histiocytesociety.org. Accessed
25.05.2017) regularly undertakes clinical trials to im-
prove treatment protocols (e.g. LCH-III study) [20].
LCH may be self-limiting or locally recurrent, but
high risk and systemic cases can have fatal outcomes,
highlighting the importance of optimal management,
in accordance to international guidelines.15
LCH is a rare disease and optimal management re-
quires interdisciplinary collaboration between special-
ists (oral surgeon, dentist, ENT, radiologist,
pathologist and oncologist). In case of unclear osteo-
lytic changes of the jawbone or unexplained diabetes
insipidus centralis, LCH should be considered as a
possible cause and biopsy should be sought to estab-
lish a definitive diagnosis. Possible differential diagno-
ses are other cutaneous histiocytosis, bone metastases
or malignant tumours and should be considered. Sur-
gical treatment of LCH is effective in localised dis-
ease, but radical excision is discouraged. In systemic
cases, relapses or high-risk disease systemic chemo-
therapy is the treatment of choice.
Fig. 8 The follow-up CBCT shows bone regeneration in the right mandible and the left maxilla in a reconstructed panoramic view (a) and bone
regeneration in the right mandible in a 3D-reconstruction (b)
Fig. 9 Follow-up FDG-PET/CT shows absence of pathologic radiotracer uptake within the lytic lesions in the right mandible (a, arrow) and the left
maxilla (b, arrow)
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